L

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

]	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
4	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Instr								
1. Name and Address <u>Hippel James</u>	of Reporting Person	·	2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]		tionship of Reporting Pers all applicable) Director	on(s) to Issuer 10% Owner		
(Last) 614 MCKINLEY	(First) PLACE NE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/19/2023	x	Officer (give title below)	Other (specify below)		
(Street) MINNEAPOLIS	MN	55413	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable L X Form filed by One Reporting Person Form filed by More than One Reporting Pers				
(City)	(State)	(Zip)	vative Securities Acquired, Disposed of, or Beneficia		ned			

2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2A. Deemed 6. Ownership 7. Nature of 5. Amount of Form: Direct (D) Execution Date, Transaction Securities Indirect (Month/Day/Year) if any Code (Instr. Beneficially Owned or Indirect (I) Beneficial (Month/Dav/Year) Following Reported Transaction(s) Ownership (Instr. 4) 8) (Instr. 4) (A) or Price (Instr. 3 and 4) Code v Amount D) Common Stock 12/19/2023 М 47,289 A \$31.26 104,850 D 12/19/2023 F 32,966 \$77.42 71,884 D Common Stock D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Options (Right to Buy)	\$31.26	12/19/2023		М			47,289	(1)	08/09/2024	Common Stock	47,289	\$ <mark>0</mark>	141,867	D	
Stock Options (Right to Buy)	\$44.33							(1)	08/08/2025	Common Stock	168,620		168,620	D	
Stock Options (Right to Buy)	\$47.6							(1)	08/07/2026	Common Stock	186,068		186,068	D	
Stock Options (Right to Buy)	\$66.97							(1)	08/05/2027	Common Stock	90,740		90,740	D	
Stock Options (Right to Buy)	\$66.97							(2)	08/05/2027	Common Stock	76,588		76,588	D	
Restricted Stock Units	(3)							(4)	(4)	Common Stock	7,780		7,780	D	
Stock Options (Right to Buy)	\$120.46							(4)	08/06/2028	Common Stock	30,400		30,400	D	
Stock Options (Right to Buy)	\$120.46							(5)	08/06/2028	Common Stock	40,536		40,536	D	
Restricted Stock Units	(3)							(6)	(6)	Common Stock	10,912		10,912	D	
Stock Options (Right to Buy)	\$94.52							(6)	08/15/2029	Common Stock	33,916		33,916	D	
Stock Options (Right to Buy)	\$94.52							(7)	08/15/2029	Common Stock	45,220		45,220	D	
Restricted Stock Units	(3)							(8)	(8)	Common Stock	13,865		13,865	D	
Stock Options (Right to Buy)	\$84.61							(8)	08/15/2030	Common Stock	37,314		37,314	D	
Stock Options (Right to Buy)	\$84.61							(9)	08/15/2030	Common Stock	45,923		45,923	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Restricted Stock Units	(3)							(10)	(10)	Common Stock	26,318		26,318	D	

Explanation of Responses:

1. Fully exercisable.

2. Options to purchase 57,440 shares are vested. Options to purchase 19,148 shares vest on 8/5/2024.

3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

4. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Options to purchase 20,268 shares are vested. Options to purchase 10,136 shares vest on 8/6/2024 and options to purchase 10,134 shares vest on 8/6/2025.

6. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

7. Options to purchase 11,304 shares are vested. Options to purchase 11,304 shares vest on each of 8/15/2025 and 8/15/2026 and options to purchase 11,308 shares vest on 8/15/2024.

- 8. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 9. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.

10. 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025.

<u>/s/ Andrew Nick as Attorney-in-</u> Fact for James Hippel pursuant to <u>12/21/2023</u> Power of Attorney previously filed

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.